Twist Bioscience Corporation Business Combination, Consideration Transferred, Equity Interests Issued and Issuable
Twist Bioscience Corporation (TWST) reported Business Combination, Consideration Transferred, Equity Interests Issued and Issuable of $1.80 million for the 1-month period ending 2023-06-30, per its 10-K filed 2024-11-18.
Financial Statements › Notes
us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable · last filed 2024-11-18
- 2023-06-30: Business Combination, Consideration Transferred, Equity Interests Issued and Issuable 1 month $1.80M.
| Period end | Business Combination, Consideration Transferred, Equity Interests Issued and Issuable 1 month |
|---|---|
| 2023-06-30 | $1.80M 10-K · filed 2024-11-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |